Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
126.20    -0.40 (-0.32%)
Bid:
125.20
Ask:
125.80
Spread: 0.60 (0.479%)
Market Cap: £307.19m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Transaction in Own Shares

5 Dec 2023 07:00

RNS Number : 6237V
PureTech Health PLC
05 December 2023
 

05 December 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

04 December 2023

Number of ordinary shares purchased:

45,974

Highest price paid per share:

156.00p

Lowest price paid per share:

150.00p

Volume weighted average price paid per share:

152.84p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,835,203 ordinary shares in treasury and has 272,632,956 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 272,632,956 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

04/12/2023

08:44:20

611

153

CHIX

00380774140TRLO0.1.1

04/12/2023

08:44:20

1222

153

XLON

00380774141TRLO0.1.1

04/12/2023

09:08:12

1222

153.2

XLON

00380776371TRLO0.1.1

04/12/2023

09:08:16

126

152.8

AQXE

00380776374TRLO0.1.1

04/12/2023

09:08:16

71

152.4

BATE

00380776375TRLO0.1.1

04/12/2023

09:08:16

318

152.4

BATE

00380776376TRLO0.1.1

04/12/2023

11:18:21

269

153.2

XLON

00380791041TRLO0.1.1

04/12/2023

11:55:30

475

153.6

CHIX

00380797013TRLO0.1.1

04/12/2023

11:55:30

1222

153.8

XLON

00380797014TRLO0.1.1

04/12/2023

11:55:30

164

153.4

BATE

00380797016TRLO0.1.1

04/12/2023

11:55:30

197

153.4

BATE

00380797015TRLO0.1.1

04/12/2023

11:55:30

52

153.6

CHIX

00380797018TRLO0.1.1

04/12/2023

11:55:30

52

153.6

CHIX

00380797017TRLO0.1.1

04/12/2023

11:55:30

32

153.6

CHIX

00380797019TRLO0.1.1

04/12/2023

11:55:30

99

152.8

TRQX

00380797020TRLO0.1.1

04/12/2023

11:55:30

116

152.8

AQXE

00380797021TRLO0.1.1

04/12/2023

12:05:51

79

153.8

CHIX

00380798920TRLO0.1.1

04/12/2023

12:05:51

345

153.8

CHIX

00380798921TRLO0.1.1

04/12/2023

13:04:24

136

154.6

AQXE

00380807288TRLO0.1.1

04/12/2023

13:33:51

611

156

CHIX

00380812520TRLO0.1.1

04/12/2023

13:33:51

1222

156

XLON

00380812521TRLO0.1.1

04/12/2023

13:33:51

361

155.4

BATE

00380812526TRLO0.1.1

04/12/2023

13:33:51

126

155.8

AQXE

00380812525TRLO0.1.1

04/12/2023

13:33:51

99

154.8

TRQX

00380812527TRLO0.1.1

04/12/2023

14:08:25

187

154.6

TRQX

00380819457TRLO0.1.1

04/12/2023

14:08:25

1222

154.6

XLON

00380819458TRLO0.1.1

04/12/2023

14:08:25

11

154.6

TRQX

00380819459TRLO0.1.1

04/12/2023

14:08:25

611

154.6

CHIX

00380819460TRLO0.1.1

04/12/2023

14:08:25

611

154.6

CHIX

00380819461TRLO0.1.1

04/12/2023

14:08:26

322

154.2

BATE

00380819462TRLO0.1.1

04/12/2023

14:08:26

5

154.2

BATE

00380819463TRLO0.1.1

04/12/2023

14:08:26

6

154.2

BATE

00380819464TRLO0.1.1

04/12/2023

14:08:26

2

154.2

BATE

00380819465TRLO0.1.1

04/12/2023

14:08:26

53

154.2

BATE

00380819466TRLO0.1.1

04/12/2023

14:08:26

306

154.2

BATE

00380819467TRLO0.1.1

04/12/2023

14:08:29

43

154

AQXE

00380819477TRLO0.1.1

04/12/2023

14:17:44

83

154

AQXE

00380821262TRLO0.1.1

04/12/2023

14:17:44

126

154

AQXE

00380821263TRLO0.1.1

04/12/2023

14:17:58

162

154.2

XLON

00380821320TRLO0.1.1

04/12/2023

14:17:58

312

154.2

XLON

00380821321TRLO0.1.1

04/12/2023

14:17:58

544

154.2

XLON

00380821322TRLO0.1.1

04/12/2023

14:18:03

196

154.2

XLON

00380821330TRLO0.1.1

04/12/2023

14:20:06

798

153.8

CHIX

00380821741TRLO0.1.1

04/12/2023

14:20:06

77

153.4

XLON

00380821742TRLO0.1.1

04/12/2023

14:20:06

1756

153.4

XLON

00380821743TRLO0.1.1

04/12/2023

14:28:57

12

154.2

XLON

00380823487TRLO0.1.1

04/12/2023

14:30:59

965

153.6

XLON

00380824523TRLO0.1.1

04/12/2023

14:30:59

149

153.6

XLON

00380824524TRLO0.1.1

04/12/2023

14:30:59

1

153.6

XLON

00380824525TRLO0.1.1

04/12/2023

14:30:59

6

153.6

XLON

00380824526TRLO0.1.1

04/12/2023

14:30:59

712

153.6

XLON

00380824527TRLO0.1.1

04/12/2023

14:31:02

361

153.4

BATE

00380824567TRLO0.1.1

04/12/2023

14:31:29

99

152.8

TRQX

00380824928TRLO0.1.1

04/12/2023

14:41:46

1065

152.8

XLON

00380828806TRLO0.1.1

04/12/2023

14:41:57

5831

152.8

XLON

00380828886TRLO0.1.1

04/12/2023

14:42:24

46

152.8

XLON

00380829243TRLO0.1.1

04/12/2023

14:43:26

1247

152.8

XLON

00380829611TRLO0.1.1

04/12/2023

14:44:08

341

152.8

XLON

00380829917TRLO0.1.1

04/12/2023

14:44:33

126

152.4

AQXE

00380830080TRLO0.1.1

04/12/2023

14:48:33

1222

152.2

XLON

00380831261TRLO0.1.1

04/12/2023

14:48:33

611

152.4

CHIX

00380831260TRLO0.1.1

04/12/2023

14:48:54

99

152

TRQX

00380831537TRLO0.1.1

04/12/2023

14:57:01

973

152.4

XLON

00380834283TRLO0.1.1

04/12/2023

15:05:33

126

152

AQXE

00380837536TRLO0.1.1

04/12/2023

15:05:33

733

152

XLON

00380837537TRLO0.1.1

04/12/2023

15:05:33

750

152

XLON

00380837538TRLO0.1.1

04/12/2023

15:05:33

350

152

XLON

00380837539TRLO0.1.1

04/12/2023

15:05:53

611

151.8

CHIX

00380837629TRLO0.1.1

04/12/2023

15:05:53

361

151.6

BATE

00380837630TRLO0.1.1

04/12/2023

15:05:53

99

151.8

TRQX

00380837631TRLO0.1.1

04/12/2023

15:05:53

611

151.6

XLON

00380837632TRLO0.1.1

04/12/2023

15:05:53

99

151.8

TRQX

00380837633TRLO0.1.1

04/12/2023

15:22:01

611

151.8

XLON

00380843591TRLO0.1.1

04/12/2023

15:28:22

525

151.6

XLON

00380845768TRLO0.1.1

04/12/2023

15:28:22

86

151.8

XLON

00380845769TRLO0.1.1

04/12/2023

15:33:35

867

151.8

XLON

00380847545TRLO0.1.1

04/12/2023

15:33:48

333

151.8

BATE

00380847845TRLO0.1.1

04/12/2023

15:35:11

424

150.4

XLON

00380848451TRLO0.1.1

04/12/2023

15:35:11

542

150.4

XLON

00380848452TRLO0.1.1

04/12/2023

15:55:48

500

152

XLON

00380857262TRLO0.1.1

04/12/2023

15:57:03

520

152

CHIX

00380857720TRLO0.1.1

04/12/2023

15:57:03

55

152.4

CHIX

00380857721TRLO0.1.1

04/12/2023

15:57:24

647

151.6

CHIX

00380857868TRLO0.1.1

04/12/2023

15:57:24

1222

151.6

XLON

00380857867TRLO0.1.1

04/12/2023

16:06:38

1

152

AQXE

00380862368TRLO0.1.1

04/12/2023

16:08:26

722

152

XLON

00380863169TRLO0.1.1

04/12/2023

16:08:34

125

152

AQXE

00380863213TRLO0.1.1

04/12/2023

16:11:54

611

152

XLON

00380864562TRLO0.1.1

04/12/2023

16:13:54

498

151.6

CHIX

00380865960TRLO0.1.1

04/12/2023

16:13:54

1222

151.6

XLON

00380865962TRLO0.1.1

04/12/2023

16:13:59

338

151.6

BATE

00380866050TRLO0.1.1

04/12/2023

16:13:59

23

151.6

BATE

00380866051TRLO0.1.1

04/12/2023

16:13:59

99

151.6

TRQX

00380866052TRLO0.1.1

04/12/2023

16:14:00

171

151.2

XLON

00380866089TRLO0.1.1

04/12/2023

16:14:22

306

151.2

XLON

00380866474TRLO0.1.1

04/12/2023

16:14:51

1

150.8

AQXE

00380866748TRLO0.1.1

04/12/2023

16:14:51

125

150.6

AQXE

00380866749TRLO0.1.1

04/12/2023

16:15:34

164

150

BATE

00380867264TRLO0.1.1

04/12/2023

16:15:34

197

150

BATE

00380867265TRLO0.1.1

04/12/2023

16:29:35

134

151

XLON

00380874032TRLO0.1.1

04/12/2023

16:29:50

365

151

XLON

00380874376TRLO0.1.1

04/12/2023

16:29:50

246

151

XLON

00380874378TRLO0.1.1

04/12/2023

16:29:51

28

151

BATE

00380874406TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFIDFDLSIIV
Date   Source Headline
4th Jun 20265:37 pmRNSHolding(s) in Company
29th May 20265:00 pmRNSHolding(s) in Company
27th May 20265:30 pmRNSHolding(s) in Company
22nd May 20265:00 pmRNSHolding(s) in Company
15th May 20267:00 amRNSCorrection - Holding(s) in Company
13th May 202612:00 pmRNS-RPRTC To Showcase Deupirfenidone at ATS Conference
8th May 20267:00 amRNSHolding(s) in Company
7th May 20266:27 pmRNSHolding(s) in Company
1st May 20267:00 amRNSPureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
29th Apr 20267:01 amRNSFinal Results
29th Apr 20267:00 amRNSPRTC Voluntarily Delists Nasdaq Depositary Shares
27th Apr 20266:09 pmRNSHolding(s) in Company
27th Apr 202612:05 pmRNS-RPRTC's Seaport Adds Neuropsychiatry Veteran to BOD
24th Apr 20265:58 pmRNSHolding(s) in Company
22nd Apr 202612:00 pmRNS-RPRTC's Gallop: Positive Ph1 Topline MDS & AML Data
16th Apr 20265:00 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSHolding(s) in Company
13th Apr 20267:05 amRNSNotice of Results
13th Apr 20267:00 amRNSPRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20266:00 pmRNS-RPRTC’s Seaport: GlyphAllo Paper Published
13th Mar 20264:35 pmRNSPDMR Notification RSU Vesting
2nd Mar 20267:00 amRNSTotal Voting Rights
25th Feb 20267:00 amRNS-RPRTC to Present at Leerink Healthcare Conference
19th Feb 20265:15 pmRNS-RPRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 202612:00 pmRNS-RPureTech to Present at the JP Morgan Conference
18th Dec 20257:00 amRNSPureTech Appoints Robert Lyne as CEO
10th Dec 20255:41 pmRNSResults of AGM on June 16, 2025 – Update Statement
10th Dec 20255:30 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RPRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
5th Dec 20256:00 pmRNS-RPRTC's Gallop: Positive Initial Topline AML Data
18th Nov 20255:30 pmRNSHolding(s) in Company
7th Nov 20256:18 pmRNSHolding(s) in Company
3rd Nov 20252:00 pmRNS-RPRTC: New LYT-200 AML Data + Update at ASH
22nd Oct 20257:00 amRNS-RPRTC: New IPF Data Show Benefit in Older Patients
17th Oct 20255:30 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSHolding(s) in Company
10th Oct 20255:59 pmRNSHolding(s) in Company
9th Oct 20256:10 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
29th Sep 20257:00 amRNS-RPRTC: New IPF Data Show Switch Patients Stabilized
24th Sep 20257:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Sep 20255:30 pmRNSHolding(s) in Company
19th Sep 20255:52 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNSHolding(s) in Company
11th Sep 202512:05 pmRNS-RPRTC's Seaport Advances 2nd Candidate Into Clinic
4th Sep 20255:30 pmRNSHolding(s) in Company
1st Sep 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report
21st Aug 202512:00 pmRNS-RPureTech Showcases Differentiated IPF Strategy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.